Average Insider

Where insiders trade, we follow

$CGEM
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Healthcare
Sector
Medical - Pharmaceuticals
Industry
Nadim Ahmed
CEO
111
Employees
$11.31
Current Price
$819.98M
Market Cap
52W Low$6.73
Current$11.3127.8% above low, 72.2% below high
52W High$23.19

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00--All Sells
Sells11$49,440.004,000
1 monthBuys00--All Sells
Sells11$49,440.004,000
2 monthsBuys00--All Sells
Sells11$49,440.004,000
3 monthsBuys00--All Sells
Sells12$222,000.0012,000
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 5, 2026
Michaelson Jennifer
Chief Scientific Officer
Sale4,000$12.36$49,440.00View Details
Sep 8, 2026
Michaelson Jennifer
Chief Scientific Officer
Sale8,000$21.57$172,560.00View Details
26 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 10, 2026
EPS
Estimated-$0.84
Actual-$0.74
Beat
Revenue
Estimated$2.00M
ActualN/A
Nov 5, 2026
EPS
Estimated-$0.84
ActualN/A
Revenue
Estimated$2.00M
ActualN/A
3 more earnings records available โ€” create a free account to see 12 months of history

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.10.12